Results 81 to 90 of about 70,211 (203)

ROLE OF TRANSFORMING GROWTH FACTOR RECEPTOR B I TYPE (TGF-BRI) IN THE PROGRESSION OF THE LUMINAL BREAST CANCER SUBTYPE

Сибирский онкологический журнал, 2017
Introduction. The crosstalk between the estrogen and growth factor receptors signaling may play an important role in the resistance to endocrine therapy.
N. N. Babyshkina, S. V. Vtorushin, T. A. Dronova, N. V. Krakhmal, M. V. Zavyalova, M. M. Tsyganov, S. V. Patalyak, E. M. Slonimskaya, N. V. Cherdyntseva   +8 more
doaj   +1 more source

Evaluation of the current knowledge limitations in breast cancer research: a gap analysis [PDF]

, 2008
BACKGROUND A gap analysis was conducted to determine which areas of breast cancer research, if targeted by researchers and funding bodies, could produce the greatest impact on patients.
A Cox, A Howell, A Kamb, A Maurice, A Moyer, A Renwick, A Rodger, Adrian Harris, AH Eliassen, AH Sims, Alastair Thompson, Angela Cox, Anthony Howell, C Julian-Reynier, C Kuperwasser, CA Purdie, CD Wagner, CH Kroenke, Charles Streuli, CJ Watson, CJ Watson, CM Perou, D Sachdev, DF Easton, Diana Harcourt, DJ Britton, DJ Hunter, DM Abd El-Rehim, DM Harcourt, DS Main, E Amir, E Katz, E Tiligada, G Bon, GP Gui, GW Sledge, H Goulding, HE Huang, Ingunn Holen, International Agency for Research on Cancer Expert Group, IO Ellis, J Bogaerts, J Brennan, J Brett, J Corner, J Debnath, J Polanowska, J Stingl, J Teulière, JJ Dignam, JK Camoriano, JL Jones, JM Bartlett, JM Dixon, JM Gee, JT Scott, Julia Gee, JW Jonker, K Polyak, K Rennstam, KA Green, KE Sleeman, Keith Brennan, KJ Fowler, KL Schwertfeger, KR Brennan, KW Kinzler, L Cortesi, L Fallowfield, L Hennighausen, L Larue, L Lostumbo, LL Northouse, LS Freedman, M Adams, M Harvie, M Harvie, M Shackleton, M Sidani, M Tanner, M Zhang, MD Holmes, MD Sternlicht, MD Sternlicht, Michael Steel, Michelle Harvie, MJ Piccart-Gebhart, ML Asselin-Labat, ML McNeely, ML McNeely, MM Ip, MO Leach, N Barnes, N Rahman, N Sarwar, NG Howlett, P Dent, P Schofield, PA Kenny, R DasGupta, R Doll, R Leake, R Scully, R Serra, RA Walker, RB Clarke, Robert Nicholson, RT Chlebowski, S Anand, S Hiscox, S Seal, S Stylianou, SA Bingham, SE Moody, SJ Cleator, SK Sharan, SN Stacey, SR Johnston, T Sheard, T Sjöblom, T Sorlie, The Breast Cancer Association Consortium, The CHEK2 Breast Cancer Case-Control Consortium, V Aranda, V Speirs, VA McCormack, VG Vogel, WD Foulkes, X Yu, YL Low   +129 more
core   +5 more sources

Association of tamoxifen resistance and lipid reprogramming in breast cancer

BMC Cancer, 2018
Background Tamoxifen treatment of estrogen receptor (ER)-positive breast cancer reduces mortality by 31%. However, over half of advanced ER-positive breast cancers are intrinsically resistant to tamoxifen and about 40% will acquire the resistance during ...
Susanne Hultsch, Matti Kankainen, Lassi Paavolainen, Ruusu-Maaria Kovanen, Elina Ikonen, Sara Kangaspeska, Vilja Pietiäinen, Olli Kallioniemi   +7 more
doaj   +1 more source

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients [PDF]

, 2014
Introduction: Inhibitors of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway can overcome endocrine resistance in estrogen receptor (ER) α-positive breast cancer, but companion diagnostics ...
Beelen, K. (Karin), Berns, P.M.J.J. (Els), Diest, P.J. (Paul) van, Koornstra, R.H.T. (Rutger), Linn, S.C. (Sabine), Muris, J.J.F. (Jettie), Opdam, M. (Mark), Severson, T.M. (Tesa), Vermorken, J.B. (Jan), Vincent, A.D. (Andrew), Wesseling, J. (Jelle)   +10 more
core   +1 more source

Targeting EPAS-1/HIF-2α Pathway to Address Endocrine Resistance in Luminal A Type Breast Cancer

Translational Oncology
Background: Tamoxifen is most often used as the first treatment for luminal A breast cancer; however, one-third of the patients are resistant to it. Numerous studies have shown that hypoxia contributes to drug resistance and is related to poor clinical ...
Enzhi Luo, Seongmin Lee, Neeraj manvi agarwal, Junjeong Choi   +3 more
doaj   +1 more source

Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.

PLoS ONE, 2019
MiR-873/CDK3 has been shown to play a critical role in ERα signaling and tamoxifen resistance. Thus, targeting this pathway may be a potential therapeutic approach for the treatment of ER positive breast cancer especially tamoxifen resistant subtype ...
Xiumei Zhang, Bingfeng Zhang, Panhong Zhang, Lihui Lian, Lianlian Li, Zhihong Qiu, Kai Qian, An Chen, Qiongqing Liu, Yinjie Jiang, Jiajun Cui, Bing Qi   +11 more
doaj   +1 more source

Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms

Frontiers in Cell and Developmental Biology, 2019
Breast cancer is the most prevalent tumor in women worldwide and about 70% patients are estrogen receptor positive. In these cancer patients, resistance to the anticancer estrogen receptor antagonist tamoxifen emerges to be a major clinical obstacle ...
Songyin Huang, Yang Chen, Zhi-Mei Liang, Zhi-Mei Liang, Na-Na Li, Na-Na Li, Yujie Liu, Yujie Liu, Yinghua Zhu, Yinghua Zhu, Dingzhun Liao, Xiao Zhen Zhou, Kun Ping Lu, Yandan Yao, Yandan Yao, Man-Li Luo, Man-Li Luo   +16 more
doaj   +1 more source

Interpatient variability in tamoxifen respone among breast cancer patient: the use of pharmacogenetics and metabolomics in closing the gaps in clinical practice / Nor Izwani Mohamed [PDF]

, 2017
Tamoxifen has been widely used as the standard adjuvant therapy for breast cancer patients with oestrogen receptor-positive status, especially in the highrisk pre- and postmenopausal women.
Mohamed, Nor Izwani
core  

TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer. [PDF]

, 2016
A subgroup of breast cancers has several metabolic compartments. The mechanisms by which metabolic compartmentalization develop in tumors are poorly characterized. TP53 inducible glycolysis and apoptosis regulator (TIGAR) is a bisphosphatase that reduces
Bartrons, Ramon, Birbe, Ruth C., Capparelli, Claudia, Caro, Jaime, Curry, Joseph M., Domingo-Vidal, Marina, Ko, Ying-Hui, Lin, Zhao, Manzano, Anna, Martinez-Outshoorn, Ubaldo E., Navarro-Sabaté, Àurea, Roche, Megan, Seifert, Erin, Tassone, Patrick, Tuluc, Madalina, Whitaker-Menezes, Diana   +15 more
core   +2 more sources

Endocrine therapy: defining the path of least resistance [PDF]

, 2014
One of the best-characterized oncogenic mechanisms in breast cancer is the aberrant activation of phosphatidylinositol-3-kinase, protein kinase B, and mammalian target of rapamycin signaling.
Musgrove, Elizabeth A., Stone, Andrew
core   +2 more sources